Paving the Way for Diversity in Clinical Trials

Hala Borno, MD, Assistant Professor of Medicine, Division of Oncology and Hematology, University of California, San Francisco

Jamie Freedman, Head of US Medical Affairs, Genentech.

Jennifer Jones-McMeans, PhD, Director of Global Clinical Affairs, Abbott Pharmaceuticals.

Marya Shegog, PhD, Health Equity and Diversity Coordinator, Lazarex Cancer Foundation.

Andrea Denicoff, RN and Nurse Consultant, National Cancer Institute; Head of Clinical Trials Operations, NCI National Clinical Trials Network.

“Lola Fashoyin-Aje, MD, Deputy Division Director and Associate Director, Science and Policy for Addressing Disparities, Center of Excellence in Oncology, FDA.

Keanna Ghazvini, Spokesperson, Pfizer Pharmaceuticals.

FDA: “Drug Trial Snapshots: NINLARO.”

National Cancer Institute: “NIH Policy and Guidelines on Inclusion of Women and Minorities as Subjects in Clinical Research”, “Inclusion of Women and Minorities as Participants in Human Subject Research”, “Cancer-related disparities”. “ Background”.

Lazarex Cancer Foundation.

Genentech biotechnology company.

Abbott Laboratories: “Abbott Announces Start of Trial to Evaluate New Espri Btk Drug-Eluting Absorbable Scaffold.”

Pfizer Pharmaceuticals.

American Cancer Society.

American Society of Clinical Oncology.

Contemporary clinical trials: “Does the COVID-19 epidemic identify a broader need for an urgent transformation of cancer clinical trials research?”

The New York Times: “Clinical trials leave the laboratory to settle in homes.”

Massey Cancer Center, Virginia Commonwealth University: “First Lady Jill Biden visits Massey to discuss cancer disparities and community-initiated research.”

ProPublica: “Black patients miss promising cancer drugs.”

Our sincere thanks to
Source link

Jothi Venkat

Leave a Reply

Your email address will not be published. Required fields are marked *